The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society (LLS) was born out of a family's grief following the death of their teenage son. Robert Roesler de Villiers, son of a well-to-do New York family, was only 16 when he quickly succumbed to leukemia in 1944. Five years later, the Robert Roesler de Villiers Foundation was born. Driven by the de Villiers' nearly boundless belief that leukemia and other blood cancers were indeed curable, the Foundation grew steadily, opening its first chapters in the New York City area. The organization was renamed The Leukemia Society of America in the 1960's to communicate a broad, national reach. LLS is the world's largest voluntary health agency dedicated to blood cancer. LLS funds lifesaving blood cancer research around the world and provides free information and support services. Our Key Priorities will ensure that: The Leukemia & Lymphoma Society helps blood cancer patients live better, longer lives.

Research
- Advance the diagnosis and treatment of blood cancers.
- Proactively establish a research agenda and direct a portion of research spending to specific areas of unmet medical need.
- Participate directly in blood cancer therapy development by expanding research beyond academic collaborations and biotech partnerships.

Patient Services
- Develop a services agenda for patients and their families.
- Inform blood cancer patients and improve access to the latest therapy and clinical trials.
- Be the key source of information and services.

Public Policy
- Increase funding from non-LLS sources.
- Encourage an effective and science-driven regulatory system.
- Ensure patients have insurance coverage.

Revenue, Marketing and Field Management
- Develop models for revenue growth.
- Increase public awareness of LLS as the leading non-profit funding impactful research and raise awareness of the impact of blood cancer research.